Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cassava Sciences is a biotechnology business based in the US. Cassava Sciences shares (SAVA) are listed on the NASDAQ and all prices are listed in US Dollars. Cassava Sciences employs 26 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $26.15 |
|---|---|
| 52-week range | $13.84 - $51.59 |
| 50-day moving average | $28.43 |
| 200-day moving average | $30.28 |
| Wall St. target price | $84.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.93 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $26.15 from 2023-03-20
| 1 week (2023-03-15) | 0.38% |
|---|---|
| 1 month (2023-02-22) | 3.61% |
| 3 months (2022-12-21) | -29.11% |
| 6 months (2022-09-22) | -48.79% |
| 1 year (2022-03-18) | N/A |
|---|---|
| 2 years (2021-03-22) | -53.14% |
| 3 years (2020-03-20) | 575.71% |
| 5 years (2018-03-21) | 276.26% |
| Gross profit TTM | $-68,032,000 |
|---|---|
| Return on assets TTM | -19.94% |
| Return on equity TTM | -31.67% |
| Profit margin | 0% |
| Book value | $5.45 |
| Market capitalisation | $1.1 billion |
TTM: trailing 12 months
We're not expecting Cassava Sciences to pay a dividend over the next 12 months.
Cassava Sciences's shares were split on a 1:7 basis on 9 May 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cassava Sciences shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Cassava Sciences shares which in turn could have impacted Cassava Sciences's share price.
Over the last 12 months, Cassava Sciences's shares have ranged in value from as little as $13.84 up to $51.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cassava Sciences's is -0.0922. This would suggest that Cassava Sciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cassava Sciences has bucked the trend.
Cassava Sciences, Inc. , a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.